Skip to content
10-K

Annual Report

Silexion Therapeutics Corp SLXN SLXNW

0001178913-26-000953

← back to feed
Filed
Mar 17, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 1.33M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 41.64K sh
Capex FY 2025 · Dec 31, 2025 $9K
Capex FY 2025 · Dec 31, 2024 $22K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$10.82M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$8.4M
Cash And Equivalents FY 2025 · Dec 31, 2025 $5.99M
Cash And Equivalents FY 2025 · Dec 31, 2024 $1.19M
Stockholders Equity FY 2025 · Dec 31, 2025 $2.6M
Stockholders Equity FY 2025 · Dec 31, 2024 −$3.99M
Current Liabilities FY 2025 · Dec 31, 2025 $2.76M
Current Liabilities FY 2025 · Dec 31, 2024 $3.52M
Total Liabilities FY 2025 · Dec 31, 2025 $4.61M
Total Liabilities FY 2025 · Dec 31, 2024 $6.85M
Current Assets FY 2025 · Dec 31, 2025 $6.64M
Current Assets FY 2025 · Dec 31, 2024 $2.25M
Total Assets FY 2025 · Dec 31, 2025 $7.22M
Total Assets FY 2025 · Dec 31, 2024 $2.86M
Eps Diluted FY 2025 · Dec 31, 2025 $8.96
Eps Diluted restated FY 2025 · Dec 31, 2024 $394.94
Eps Basic FY 2025 · Dec 31, 2025 $8.96
Eps Basic restated FY 2025 · Dec 31, 2024 $394.94
Sga Expense FY 2025 · Dec 31, 2025 $4.49M
Sga Expense FY 2025 · Dec 31, 2024 $6.76M
Rd Expense FY 2025 · Dec 31, 2025 $7.14M
Rd Expense FY 2025 · Dec 31, 2024 $5.82M
Net Income FY 2025 · Dec 31, 2025 −$11.91M
Net Income FY 2025 · Dec 31, 2024 −$16.52M
Operating Income FY 2025 · Dec 31, 2025 −$11.63M
Operating Income FY 2025 · Dec 31, 2024 −$12.57M